Day: December 18, 2024

Oracle Health partnership enables 400-bed Texas-based health system to leverage RevID’s automated charge reconciliation to improve financial performance ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of RevID with a 400-bed, Oracle Health-EHR based health system with facilities in Western Texas. The deal was closed in partnership with Oracle Health. Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation enables hospitals to capture 100% of earned revenue by eliminating charge capture gaps and accelerates cash flow by...

ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (Nasdaq: PESI) (“Perma-Fix” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 2,200,000 shares of its common stock at a price to the public of $10.00 per share. Perma-Fix expects the gross proceeds from the offering to be approximately $22 million before deducting the underwriting discount and other estimated offering expenses. In connection with the offering, Perma-Fix has granted the underwriter a 30-day option to purchase up to 330,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about December 19, 2024, subject to the satisfaction of customary closing conditions. Perma-Fix intends to use the net...

– Improvements Across Measures of Behavior, Function, Cognition and Movement – – Expediting Plans to Advance CT1812 into Late-Stage Trials – – Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) – – Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data – PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies...

The touch controller is designed to integrate with a comprehensive ecosystem of tools to streamline development and speed time to market CHANDLER, Ariz., Dec. 18, 2024 (GLOBE NEWSWIRE) — Turnkey touch controllers are a fast and easy way to upgrade from mechanical buttons to modern touch buttons or displays. With the launch of its 12-button MTCH2120 touch controller, Microchip Technology (Nasdaq: MCHP) is providing designers with a straightforward pathway for implementing touch button capabilities on user interfaces. The low-power, water-tolerant turnkey touch device is integrated with Microchip’s unified ecosystem, allowing for an easier design process and facilitating transitions between other turnkey solutions and MCU-based touch implementations. The MTCH2120 is the first of what will be a family of I2C-based touch controllers...

FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments...

                                                                                                          Lysaker, 18 December 2024 Storebrand Asset Management AS hereby announces a unitholder meeting in Storebrand Indeks – Nye Markeder to be held on 13 January 2025. Background and Purpose Storebrand Asset Management proposes amendments to the Articles of Association for the Storebrand Indeks-Nye Markeder fund. The proposed changes will allow the fund to invest in companies with a weighting exceeding 10% of the benchmark index, ensuring that the fund can continue to reflect the characteristics of its benchmark index. This adjustment has become necessary as one company within the fund’s benchmark index, the MSCI Emerging Markets Index, represented 10% of the index as of October 30, 2024. The proposed amendment will align the...

NORWALK, Conn., Dec. 18, 2024 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced the appointment of Barak Eilam to its Board of Directors. He will also serve on FactSet’s Compensation and Talent Committee. Eilam brings nearly three decades of experience scaling enterprise software companies into global market leaders. He is serving as Chief Executive Officer (CEO) of NICE, a leading enterprise software company specializing in analytics and AI solutions, through the end of calendar year 2024. As CEO from 2014 to 2024, Eilam led the company through remarkable growth, tripling its revenue to nearly $3 billion, growing cloud revenue from almost zero to $2 billion, and more than quadrupling earnings per share. He began his career as an engineer...

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka’s addition will become effective prior to market open on Monday, December 23rd, 2024. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average...

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease. “Alongside the FDA’s orphan drug designation in the U.S., the European Commission’s orphan medicinal product designation for mitapivat underscores the urgent need for novel therapies for sickle cell disease and highlights its potential to provide clinically meaningful...